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Abstract
Background—An abdominal aortic aneurysm (AAA) is an abnormal ballooning of the major
abdominal artery. Some AAAs present as emergencies and require surgery; others remain
asymptomatic. Treatment of asymptomatic AAAs depends on many factors but an important one
is size of the aneurysm, as risk of rupture increases with aneurysm size. Large asymptomatic
AAAs (> 5.5 cm in diameter) are usually operated on; very small AAAs (< 4.0 cm diameter) are
monitored with ultrasonography. The optimal timing of surgery would benefit from further
evidence.
Objectives—This review compared long-term survival in patients with AAAs of diameter 4.0 to
5.5 cm who received immediate repair versus routine ultrasound surveillance.
Search methods—For this update the Cochrane Peripheral Vascular Diseases Group searched
their Specialised Register (February 2012) and CENTRAL (2012, Issue 1). Reference lists of
relevant articles were checked for additional studies and the searches were supplemented by
handsearches of recent conference proceedings and information from experts in the field.
Selection criteria—Randomised controlled trials in which men and women with asymptomatic
AAAs of diameter 4.0 to 5.5 cm were randomly allocated to immediate repair or imaging-based
surveillance at least every six months. Outcomes had to include mortality or survival.
Data collection and analysis—Two authors (GF, MAMM) abstracted the data, which were
cross-checked by the other authors (DJB, JTP). Due to the small number of trials, formal tests of
heterogeneity and sensitivity analyses were not conducted.
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Main results—Four trials with a combined total of 3314 patients, the UK Small Aneurysm Trial
(UKSAT), the Aneurysm Detection and Management (ADAM) trial, the Comparison of
Surveillance Versus Aortic Endografting for Small Aneurysm Repair (CAESAR), and the Positive
Impact of Endovascular Options for treating Aneurysms Early (PIVOTAL) fulfilled the inclusion
criteria. The four trials showed an early survival benefit in the surveillance group (due to 30-day
operative mortality with surgery) but no significant differences in long-term survival (adjusted
hazard ratio (HR) 0.88, 95% confidence interval (CI) 0.75 to 1.02, mean follow up 10 years
(UKSAT); HR 1.21, 95% CI 0.95 to 1.54, mean follow up 4.9 years (ADAM); HR 0.76, 95% CI
0.30 to 1.93, median follow up 32.4 months (CAESAR); HR 1.01, 95% CI 0.49 to 2.07, mean
follow up 20 months (PIVOTAL)). The meta analyses of mortality at one year (CAESAR and
PIVOTAL only) and six years (UKSAT and ADAM only) revealed a non-significant association
(Peto odds ratio at one year 1.15, 95% CI 0.59 to 2.25; Peto odds ratio at six years 1.11, 95% CI
0.91 to 1.34).
Authors’ conclusions—The results from the four trials to date demonstrate no advantage to
early repair (via open or endovascular surgery) for small AAA (4.0 to 5.5 cm) and suggest that
‘best care’ for these patients favours surveillance. Furthermore, the more recent trials focused on
the efficacy of endovascular aneurysm repair and still failed to show benefit. Thus, both open and
endovascular repair of small AAAs are not supported by currently available evidence.
Medical Subject Headings (MeSH)
Aortic Aneurysm, Abdominal [mortality; *surgery; ultrasonography]; Cost-Benefit Analysis;




Description of the condition
An aneurysm is an abnormal dilatation of an artery. This can occur in any artery including
the abdominal aorta, below the branches to the renal arteries (Ernst 1993; Stonebridge
1996). Abdominal aortic aneurysms (AAAs) are rare in people under 50 years of age, but
thereafter prevalence increases sharply with increasing age (ADAM). AAAs occur in about
5% of men aged 65 to 74 years and are approximately three times more common in men
than in women (ADAM). Low prevalence rates have been observed for African American
males compared to Caucasian males and black race has been identified as having a strong
negative association with AAA (ADAM).
The cause of AAA is likely to be multifactorial (Shah 1997). It may result from a change in
the composition of the collagen and elastin matrix in the media of the arterial wall due to
excessive proteolysis. AAAs often coincide with atherosclerosis in the aortic wall but it is
not known if atherosclerosis is involved in the pathogenesis of aneurysms. Inflammation of
the aortic wall also appears to be influential. The main well-established risk factor is
cigarette smoking, with smokers having a two-to three-fold increased risk of AAA compared
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to non-smokers (ADAM; Lederle 2003). Aneurysms also occur more frequently in close
relatives of patients who suffered an AAA, but a mode of inheritance has not been
demonstrated (Ballard 1999).
The progression of AAA can vary considerably (Ernst 1993). Some people remain
asymptomatic throughout life while others present with symptoms such as back pain or a
pulsating abdominal mass; or as emergencies following rupture. The risk of rupture
increases with aneurysm size and mortality following rupture is high (approximately 60%
die before reaching hospital) (Ballard 1999).
Description of the intervention
Ruptured AAAs require emergency surgical repair, which has a mortality rate of 40% to
50%. The outcome of surgery is highly dependent on the patient’s presenting features,
including general clinical condition (Ernst 1993; Stonebridge 1996). Surgery for patients
with symptomatic AAAs is considered necessary to relieve symptoms and to reduce the risk
of rupture and death.
In the case of asymptomatic AAAs, however, management depends on the size of the
aneurysm. To date, no medical therapy has been shown to reduce the rate of size change or
risk of rupture among patients with asymptomatic AAAs (Ballard 1999; Ernst 1993;
UKSAT); however, several studies are currently ongoing (personal communication JTP).
Surgery is performed on larger aneurysms (> 5.5 cm in diameter) while very small
aneurysms (< 4.0 cm in diameter), in which the risk of rupture is low, are monitored for
growth through regular imaging, usually ultrasonography. For small AAAs (4.0 to 5.5 cm
diameter) there has been considerable debate as to the most beneficial course of treatment;
that is, immediate repair versus surveillance and selective repair of AAAs that subsequently
enlarge (Lederle 1996). Much of this debate centres around the uncertainty of risk of rupture
for small AAAs.
How the intervention might work
A literature review conducted by a RAND Corporation panel in 1991 assessed the
appropriateness and necessity of surgery for AAAs and found reports of risk of rupture,
based on referral case series, as high as 5% per year for AAAs > 5.0 cm and of 3% to 5%
per year for AAAs ≤5.0 cm (Ballard 1992), which supports arguments in favour of the
aggressive approach of immediate repair. Population data, however, suggest that risk of
rupture for AAAs < 5.0 cm is less than 1% per year (Ballard 1992; Nevitt 1989), under
which scenario the merits of selective surveillance are apparent. Similarly, population
studies suggest that early reports of expansion rates of approximately 0.4 cm/year for AAAs
between 4.0 cm and 6.0 cm in diameter (Bernstein 1984) had overestimated growth by
approximately 0.2 cm/year (Nevitt 1989), inaccurately favouring aggressive intervention.
Why it is important to do this review
The ‘grey area’ of care for small AAAs, resulting from the uncertainty surrounding the risk
of rupture versus the risk of intervention and expansion rates identified by the RAND panel,
highlighted the need for randomised controlled trials comparing immediate surgery and
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selective surveillance as treatment options. This led to the design of the Aneurysm Detection
and Management (ADAM) trial (ADAM), the United Kingdom Small Aneurysm Trial
(UKSAT) (UKSAT), and the Canadian Trial, which used open surgery to perform the
repairs. Later, when endovascular repair became available, the Comparison of Surveillance
Versus Aortic Endografting for Small Aneurysm Repair (CAESAR) and the Positive Impact
of Endovascular Options for treating Aneurysms Early (PIVOTAL) were conducted, using
endovascular repair as the surgical option.
OBJECTIVES
To compare mortality, quality of life, and cost effectiveness of early or immediate surgical
repair versus routine ultrasound surveillance in patients with asymptomatic AAAs between
4.0 cm and 5.5 cm in diameter.
METHODS
Criteria for considering studies for this review
Types of studies—Randomised controlled trials (RCTs) in which patients were randomly
allocated to early or immediate surgery versus ultrasound surveillance.
Types of participants—Men or women of any age with an asymptomatic AAA. The
aneurysm was restricted to the abdominal aorta distal to the renal arteries. The maximum
antero-posterior diameter, measured using ultrasound or computerised tomography (CT)
scanning, must have been at least 4.0 cm and less than 5.5 cm. The aneurysm should have
been non-tender on examination and the patient assessed as generally fit for surgery.
Types of interventions—Surgical repair of the aneurysm consisting of insertion of a
prosthetic inlay graft either by open surgery (abdominal or retroperitoneal route) or by
endovascular repair. Surveillance of the maximum antero-posterior diameter was to be
performed regularly, with a maximum interval of six months.
Types of outcome measures
Primary outcomes: The outcome measures included at least one of the following:
• life expectancy, expected number of years of life remaining following
randomisation;
• mortality, death rate during a specified period of time following randomisation;
• quality of life, a standard generic measure using a validated instrument
encompassing typical domains such as pain, health perceptions, mental health, and
physical and social functioning.
Secondary outcomes: The costs, from trial data, a specific survey, or routine statistics,
which might have included:
• direct hospital costs, all hospital costs attributable to inpatient stays, surgery, and
out-patient attendances including ultrasound surveillance;
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• other health service costs, non-hospital costs such as general practitioner
attendances, ambulance transfers, convalescence;
• societal costs, non-health service costs to society such as loss of productivity, time
off work, sickness benefit.
The following outcome measures were of interest but were not included in a meta-analysis
because they were relevant to only one arm of a trial or were of doubtful validity:
• cause of death, mortality by underlying cause of death according to the
International Classification of Diseases;
• operative mortality, measured as 30-day or ‘in hospital’ mortality;
• rupture, rate of aneurysm rupture diagnosed at postmortem, operation, or certified
as the underlying cause of death.
Search methods for identification of studies
Electronic searches—For this update, the Cochrane Peripheral Vascular Diseases Group
Trials Search Co-ordinator (TSC) searched the Specialised Register (February 2012) and the
Cochrane Central Register of Controlled Trials (CENTRAL) (2012, Issue 1), part of The
Cochrane Library (www.thecochranelibrary.com). See Appendix 1 for details of the search
strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and
is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED,
and through handsearching relevant journals. The full list of the databases, journals, and
conference proceedings which have been searched, as well as the search strategies used, are
described in the Specialised Register section of the Cochrane Peripheral Vascular Diseases
Group module in The Cochrane Library (www.thecochranelibrary.com).
Searching other resources—The reference lists of relevant studies were checked. The
searches were supplemented by information from experts in the field and from handsearches
of the following conference proceedings.
• The International Society for Vascular Surgery Congress (through to 2011).
• The Society for Vascualr Surgery Annual Meeting (through to 2011).
• The Society for Clinical Vascular Surgery Annual Symposium (through to 2011).
• The European Society for Vascular Surgery Annual Meeting (through to 2010).
Data collection and analysis
Selection of studies—The trials comparing surgical repair versus selective surveillance
for small AAAs were identified by DJB, GF, MAMM, and JTP.
Data extraction and management
For the update, two authors (GF and MAMM) abstracted the data, which were cross-
checked by the other authors (DJB and JTP). The data collected on each trial included
information on the participants (age and sex distribution, aneurysm size), the interventions
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(graft type, frequency of ultrasound surveillance), and the outcomes (as specified in ‘Criteria
for considering studies for this review’).
Assessment of risk of bias in included studies
The four authors discussed each of the trials and agreed on their inclusion or exclusion based
on the adequacy of the random allocation, attainment of adequate sample size, and
completeness of follow up. The nature of the interventions did not permit participants or
observers to be blinded and so this lack did not disqualify trials from inclusion. In addition,
the risk of bias of the included studies was assessed using the ‘Risk of bias’ tool as described
in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).The
following domains were assessed and judged to be at low risk of bias, high risk of bias, or
unclear risk of bias: selection bias, performance and detection bias, attrition bias, reporting
bias, and other sources of bias.
Measures of treatment effect
Odds ratios (ORs) (30-day mortality) and hazard ratios (HRs) (long-term survival) were
estimated to assess the efficacy of the intervention in each study.
Unit of analysis issues
Patients with AAAs of diameter 4.0 to 5.5 cm who received immediate surgical repair
versus routine ultrasound surveillance.
Dealing with missing data
None of the studies included in this review used single or multiple imputation procedures to
deal with missing data. However, the incidence of missing data was very low.
Assessment of heterogeneity
Due to the small number of trials, a qualitative presentation of the trial results is reported in
the present review. Meta-analyses of mortality at one year and six years were performed.
Heterogeneity was assessed using the I2 statistic. We considered values of I2 of 50% or
greater to indicate substantial heterogeneity. Where heterogeneity was identified, reasons for
it were explored.
Assessment of reporting biases
Given the qualitative nature of the present review, formal statistical tests were not carried
out. However, all included studies published findings on the main study outcome of this
review.
Data synthesis
Due to the small number of trials, the present review focused on a qualitative presentation of
the trial results. However, fixed-effect model meta-analyses of mortality at one year and six
years, estimating Peto ORs and 95% confidence intervals (CIs), were also presented.
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Subgroup analysis and investigation of heterogeneity
Due to the small number of trials, a subgroup analysis was not carried out.
Sensitivity analysis
Due to the small number of trials, a sensitivity analysis was not carried out.
RESULTS
Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.
Results of the search
Four relevant randomised controlled trials were identified from the electronic searches
(ADAM; CAESAR; PIVOTAL; UKSAT) and one from personal communication (Canadian
Trial).
Included studies
Four studies, the UKSAT (UKSAT), ADAM (ADAM), CAESAR (CAESAR), and
PIVOTAL (PIVOTAL) trials, fulfilled the criteria for consideration in the present review.
Patient inclusion and exclusion criteria for the studies were comparable. All the trials
enrolled patients with small (4.0 to 5.5 cm) non-tender, asymptomatic AAAs and who were
considered to be fit for immediate surgery. The four trials excluded patients who were
considered unfit for immediate surgery, had symptoms associated with the aneurysm, were
unable to attend the follow-up visit, or were unable to give informed consent. The ADAM
study further excluded patients who: received a revascularisation procedure within three
months of enrolment, had a myocardial infarction within six months of enrolment, or were
expected to survive less than five years because of invasive cancer or another life-
threatening disease. The CAESAR trial, besides excluding those patients not anatomically
suitable for endovascular repair, further excluded patients who had severe comorbidities or a
suprarenal or thoracic aorta ≥4.0 cm in diameter, or needed urgent repair. The PIVOTAL
study further excluded patients who had an abdominal or thoracic repair, an aneurysm
originating ≤1.0 cm from the most distal main renal artery, life expectancy of < 3 years,
Society for Vascular Surgery (SVS) score > 2 with the exception of age and controlled
hypertension, baseline serum creatinine level > 2.5 mg/dL, or when the patient did not meet
the indications for use of the endograft device.
Lastly, age inclusion criteria were 50 to 79 years, 50 to 79 years, 40 to 90 years, and 60 to
76 years for the ADAM, CAESAR, PIVOTAL and UKSAT studies, respectively. Despite
the relatively wider age range eligible for inclusion in the ADAM, CAESAR, and PIVOTAL
trials, the majority of the participants fell within the same age range as the UKSAT trial:
88%, approximately 70%, and approximately 70%, respectively, which is perhaps
unsurprising given that AAA prevalence is much higher in older age groups. In total, 3314
patients with asymptomatic AAAs of antero-posterior diameter 4.0 to 5.5 cm were
randomised to immediate surgery (n = 1680: 569 in ADAM, 182 in CAESAR, 366 in
PIVOTAL, and 563 in UKSAT; 50.7%) or routine ultrasound or computed tomography
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surveillance every six months (three months if diameter 5.0 to 5.5 cm in ADAM and
UKSAT) (n = 1634: 567 in ADAM, 178 in CAESAR, 362 in PIVOTAL, and 527 in
UKSAT; 49.3%). The primary outcome was all-cause mortality and secondary measures
were AAA-related death, morbidity and quality of life. Follow up for vital status ranged
from: 3.5 to 8.0 years (mean 4.9 years) in the ADAM trial, median 32.4 months (IQR 21.0 to
44.1) in the early endovascular repair group and 30.9 (IQR 18.3 to 45.3) in the surveillance
group in CAESAR trial, 20 ± 12 months (range 0 to 41 months) in the PIVOTAL trial, and
up to 12 years (range 8 to 12 years, mean 10 years) in the UKSAT trial. Approximately 95%
and 90% of patients were alive at one and two years after randomisation, respectively, in the
ADAM and UKSAT trials. Thereafter, survival rates decreased more rapidly in the UKSAT
study. The 5-year survival rate was approximately 70% in the UKSAT study and
approximately 80% in the ADAM trial. The 12-year survival rate was approximately 35% in
the UKSAT trial. In the CAESAR trial there was no difference in the all-cause mortality of
the immediate surgery and selective surveillance groups (hazard ratio (HR) 0.76, 95% CI
0.30 to 1.93, P = 0.6) and at 54 months the cumulative probability of mortality was 14.5% in
the early endovascular repair and 10.1% in the surveillance group, and aneurysm-related
mortality was < 1% in both groups. In the PIVOTAL trial the overall mortality was 4.1% in
both groups (HR 1.01, 95% CI 0.49 to 2.07, P = 0.98) and the aneurysm related mortality
was < 1% in both groups.
Excluded studies
The trial that did not fulfil the criteria for consideration was the Canadian Trial, which ended
early because of inadequate recruitment (Cole CW, personal communication, 1998) and was
not sufficiently complete for inclusion in this review.
Risk of bias in included studies
The UKSAT, ADAM, CAESAR, and PIVOTAL are the trials to date which met the
inclusion criteria. Study designs were similar with patients randomly allocated to either
immediate surgery or selective surveillance. In the four trials most patients assigned to the
immediate surgery group received endovascular or standard open repair within six weeks of
randomisation. Likewise, in all four trials patients assigned to selective surveillance were
followed, without repair, at regular intervals (at minimum once every six months) and
surgery was performed within six weeks if: a) the aneurysm reached 5.5 cm in diameter; or
b) the aneurysm enlarged by a minimum of 0.7 cm in six months (ADAM), 1.0 cm in one
year (ADAM), greater than 1.0 cm in one year (CAESAR), or a minimum of 0.5 cm
between two 6-month assessments (PIVOTAL); or c) the aneurysm became symptomatic.
Adherence to assigned treatment was very high across the four trials (UKSAT had the
lowest adherence rate at 92.6%) and at the end of the trials mortality status was ascertained
in 100% (ADAM; PIVOTAL; UKSAT) and 98% (CAESAR) of participants. Approximately
62%, 48%, 31%, and 75% of the patients in the selective surveillance group of the ADAM,
CAESAR, PIVOTAL, and UKSAT studies, respectively, eventually underwent aneurysm
repair.
See also Figure 1 and Figure 2 for the ‘Risk of bias’ summary.
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The methods of randomisation of the included studies ensured good balance across study
groups. Adherence to assigned treatment was high, with the lowest adherence rate across the
four trials at 92.6%. Risk of allocation bias was very low.
Blinding
The nature of the interventions did not permit participants or observers to be blinded.
Incomplete outcome data
Mortality status was ascertained in 100% (ADAM; PIVOTAL;UKSAT) and 98%
(CAESAR) of participants. Moreover, the included studies experienced low loss to follow-
up rates. Risk of attrition bias was very low.
Selective reporting
All included studies published findings on the main study outcome of this review. Risk of
selective reporting bias was very low.
Other potential sources of bias
The CAESAR trial was originally funded by Cook Medical. During the enrolment phase of
the trial, in December 2006, the sponsorship withdrew. However, the trial continued as full
spontaneous research. According to the CAESAR study team the design, data collection,
data analysis, data interpretation, and the writing of reports regarding the trial were at all
times conducted independently from the sponsor. In summary, we could not exclude a
possible conflict of interests in the CAESAR trial given that Cook Medical, the sponsor of
the study, withdrew. The PIVOTAL trial was sponsored by Medtronic Vascular, who hold
the database. Conflicts of interest were declared for two members of the PIVOTAL research
team, who received funding from Medtronic and were consultants; a third member of the
PIVOTAL research team had previously been a consultant for Medtronic. The Vascular
Surgery Academic Coordinating Center of the Cleveland Clinic was independently
responsible for the conduct of the study and its analysis. Other potential sources of bias for
the remaining trials included in this review were not identified and are therefore unclear.
Effects of interventions
In both the UKSAT (UKSAT) and ADAM (ADAM) studies, the 30-day operative mortality
in the immediate surgery group (5.5% UKSAT and 2.1% ADAM) led to an early
disadvantage in terms of survival in this study group. The lower 30-day operative mortality
rate observed in the ADAM trial was expected due to the more restrictive study inclusion
and exclusion criteria of the trial and better lung and renal function of the participants. In the
CAESAR and PIVOTAL trials, the 30-day operative mortality in the immediate surgery
group (0.6% CAESAR and 0.3% PIVOTAL) led to an early disadvantage in terms of
survival in this study group. The lower 30-day mortality rate observed in the CAESAR and
PIVOTAL studies was expected due to the use of endovascular repair.
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In the UKSAT study, the long-term mortality rate (range 8 to 12 years, mean 10 years) was
63.9% in the immediate surgery group and 67.3% in the surveillance group. The UKSAT
investigators found no statistically significant difference in long-term survival between the
immediate surgery and surveillance groups (adjusted hazard ratio (HR) 0.88, 95% CI 0.75 to
1.02). However, the hazards were non-proportional among study groups, as revealed by the
survival curves crossing at approximately the three-year mark: the risk associated with
operative mortality in the immediate repair group had resulted in an initial survival
disadvantage for this study group compared to the selective surveillance group. The
estimated adjusted HRs were in the direction of greater benefit of early surgery for younger
patients and those with larger aneurysms but none of the tests for interaction were
statistically significant. In contrast, recent analysis has suggested that the least fit patients
benefited most from a policy of early surgery, although again the test of interaction was not
significant (Brown 2008).
At the end of the study follow up (range 3.5 to 8.0 years, mean 4.9 years) the observed
mortalities for the ADAM trial in the immediate repair and the selective surveillance groups
were 25.1% and 21.5%, respectively. However, in the UKSAT study the long-term survival
was not statistically significantly different between study groups (adjusted HR 1.21, 95% CI
0.95 to 1.54). The authors did not report violation of the proportional hazard assumption.
Study results showed a possible modification of effect with age and AAA size but, as in the
UKSAT study, none of the tests for interaction were significant.
At the end of the study follow up (54 months, median 32.4 months) the estimated all-cause
mortalities for the CAESAR trial in the immediate surgery group and the selective
surveillance groups were 14.5% and 10.1% respectively. However, in the CAESAR study
the long-term survival was not statistically different between study groups (HR 0.76, 95%
CI 0.30 to 1.93, P = 0.6). The authors did not report a violation of the proportional hazard
assumption.
At the end of the study follow up (range 0 to 41 months, mean 20 ± 12 months) the
estimated all-cause mortalities for the PIVOTAL trial in the immediate surgery group and
the selective surveillance groups were both 4.1%. However, in the PIVOTAL study the
long-term survival did not significantly differ between groups (HR 1.01, 95% CI 0.49 to
2.07, P = 0.98). The authors reported no evidence of non-proportional hazards between the
two groups over time.
Meta-analyses of mortality were performed at one year for all four trials and at six years for
the ADAM and UKSAT trials (the tabular data for analysis at this time point were available
only for these studies). The meta analyses of mortality at one year to assess the effect of
endovascular aneurysm repair (EVAR) (CAESAR and PIVOTAL only) and open surgery
(UKSAT and ADAM only) and both EVAR and open surgery (CAESAR; PIVOTAL;
UKSAT; ADAM) revealed a non-significant greater risk of mortality (Peto odds ratio (OR)
1.15, 95% CI 0.59 to 2.25, I2 = 0%) with early EVAR (Figure 3) and significantly higher
risk of mortality with early open surgery (Peto OR 1.60, 95% CI 1.10 to 2.32, I2 = 0%)
(Figure 4) or early repair by either method (Peto OR 1.48, 95% CI 1.07 to 2.05, I2 = 0%)
(Figure 5). The meta analysis of mortality at six years (UKSAT and ADAM only) revealed a
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non-significantly higher risk of mortality associated with early open surgery (Peto OR at six
years 1.11, 95% CI 0.91 to 1.34, I2 = 0%) (Figure 6).
In the UKSAT trial (UKSAT), the mean health service costs per patient were higher in the
surgery than the surveillance group (£4978 versus £3194; difference £1064, 95% CI 796 to
1332). This estimate accounted for surveillance visits, aneurysm repair, and any associated
follow up. For example, if surveillance was conducted only once per annum, the mean cost
difference in favour of surveillance widened to £1256 (95% CI 990 to 1522). A 25%
increase in cost of aneurysm repair further increased the difference, to £1636 (95% CI 1340
to 1932). While neither the CAESAR nor PIVOTAL trials reported a cost comparison, the
fact that the cost of endovascular repair is generally greater than that of the open repair used
in the UKSAT means the cost difference would likely be even greater.
In the UKSAT trial, quality of life at randomisation was similar in the two groups but early
surgery patients reported minor improvements in current health perceptions and less
negative changes in bodily pain. In the CAESAR trial, comparable quality of life (SF-36)
scores were seen in the immediate endovascular repair and surveillance groups at
randomisation. At six months the total SF-36 and the Physical and Mental domain scores
were all significantly higher with respect to baseline in the immediate repair group, while
patients in the surveillance group scored lower. However, differences between the two
groups diminished over time so that at the last assessment (one year or more after
randomisation) there was no significant difference between immediate repair and
surveillance (P = 0.25).
DISCUSSION
The results from the four trials to date suggest no overall advantage to early surgery for
small AAA. They do not allow additional guidelines for ‘best-care’ management of
subgroups of patients since the trials did not provide data allowing analysis of results in
these subgroups in relation to the intervention versus control and specified end-points.
Furthermore, the more recent trials focused on the efficacy of EVAR and still failed to show
benefit. Thus, both open and endovascular repair of small AAAs is not supported by
currently available evidence. While the development of EVAR technology offers a
significantly reduced operative mortality compared to open surgery and better short-term
survival in general (Lederle 2009; Prinssen 2004; United Kingdom EVAR Trial
Investigators 2010), reflected in the differences observed between Figure 3 and Figure 4, its
efficacy is limited by high rates of re-operation for complications unique to EVAR. These
include stent migration, stent wire fracture, metal fatigue, graft insertion site problems, and
endoleak (Wilt 2006) over longer follow up (Becquemin 2011; De Bruin 2010; EVAR trial
participants 2005). For small AAA, in particular, early EVAR does not appear to be superior
to surveillance (see Figure 3, which shows a non-significant benefit in favour of
surveillance) and its use could expose patients to unnecessary risk and ultimately higher
healthcare costs (Ballard 2012). Likewise, as seen in Figure 4 and Figure 6, open repair
offers no superior outcomes compared to surveillance for patients with small AAAs.
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Establishing optimal treatment guidelines for patient with small AAAs becomes even more
relevant to improving public health and patient outcomes when the likelihood of increased
AAA screening in the future is taken into account. The evidence from three randomised
population screening trials, summarised in a Cochrane review, shows the benefits of
screening older men for AAA (Cosford 2007). A national screening programme for all men
aged 65 years and older has started in the UK (UK Screeening). The US Preventive Services
Task Force (USPSTF) recommend AAA screening for men aged 65 to 75 years who have
ever smoked (U.S. Preventive Task). More recently the Society for Vascular Surgery
recommended screening of all men aged 60 to 85 years for AAA; women aged 60 to 85
years with cardiovascular risk factors; and men and women aged 50 years and older with a
family history of AAA (Kent 2004). These recommendations are based on evidence that
screening for AAA and repair of large AAAs (5.5 cm or more in diameter) leads to
decreased AAA-specific mortality. However, the USPSTF also indicates that there is
possible evidence of harms of screening and early treatment, including an increased number
of surgeries with associated clinically-significant morbidity and mortality, and short-term
psychological harms (U.S. Preventive Task). These harms are of most concern for patients
with aneurysms in the 4.0 to 5.5 cm AAA size range, for whom current treatment guidelines
are ambiguous.
Summary of main results
Findings from this review indicate that there was no survival advantage with immediate
repair compared to selective surveillance in participants with asymptomatic aneurysms sized
4.0 to 5.5 cm in diameter. Results from the UKSAT, ADAM, CAESAR, and PIVOTAL
trials showed no significant differences in survival between the study treatment groups for
patients with AAA in particular size ranges or for patients in a particular age group.
Uncertainty regarding the management of small AAAs is demonstrated by the current
clinical guidelines, which do not provide any explicit therapeutic recommendation for AAAs
in the range of 4.0 to 5.5 cm (Hirsch 2006; Wilt 2006). The management of small AAAs
remains a grey area in clinical practice. Data regarding key factors for the management of
AAA (such as AAA size; patient age, gender, and fitness) are much needed for the
development of more definite and precise guidelines. In particular, examining the survival
effect of immediate surgery versus selective surveillance for specific AAA size, AAA shape,
and AAA location could reduce the uncertainty regarding the management of small AAA.
In summary, findings from the four trials to date suggest no advantage to early surgery for
small AAA. Furthermore, the more recent trials focused on the efficacy of EVAR and still
failed to show benefit. Thus, both open and endovascular repair of small AAAs is not
supported by currently available evidence. The Society for Vascular Surgery guidelines
strongly recommend surveillance for patients with a fusiform AAA of 4.0 to 5.4 cm
(Chaikof 2009).
Overall completeness and applicability of evidence
This review is based on all trials to date which were suitable for inclusion. However, one
limitation of the present review is the low proportion of women and non-Caucasian races in
the trials. However, gender imbalance is exacerbated by the late onset of the disease in
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women and by the higher prevalence of AAA (approximately three times higher) in men
than in women (Lederle 1997; Lederle 2000); and black race has been identified as having a
strong negative association with AAA (ADAM). Thus, while it is indisputable that study
results might be difficult to generalise to women and non-Caucasian men, this review
provides critical data that can benefit the population with the highest prevalence of AAA
and, therefore, the vast majority of patients with AAA. Future research regarding the
management of small AAA should focus on minorities and women as data regarding these
populations are lacking. In particular, future research should assess whether the AAA
management recommendations, which are based on studies in which women are under-
represented, are applicable to women given their smaller body frames and, therefore, smaller
abdominal aortas. This is critical given the higher risk of rupture experienced by women, the
risk of rupture of small AAAs is four times higher in women than in men (Brown 2003).
Quality of the evidence
The UKSAT, ADAM, CAESAR, and PIVOTAL trials were very similar in design and,
more importantly, were all well-conducted studies. All relevant studies were identified and
included in this review. Moreover, all relevant data were obtained. In summary, besides the
possible bias deriving from the conflict of interest regarding the CAESAR trial, the quality
of evidence summarized in this review is sound.
Potential biases in the review process
Two authors (GF, MAMM) independently abstracted the data, which were cross-checked by
the other authors (DJB, JTP). To further reduce bias, the role of JTP (trialist in the UKSAT
study and author in the present review) in abstracting the data was limited to cross-checking
the information abstracted by GF and MAMM. Strengths of the present review regarding
potential biases are: 1) all relevant studies were identified and included in the review; 2) all
the studies included in the review had very similar designs and methods; 3) relevant data for
all studies were obtained; and 4) all the studies included in the review shared the same main
outcome, and this outcome is the outcome of interest for this review too. As reported,
however, we can not exclude possible bias deriving from the conflict of interest regarding
the CAESAR and PIVOTAL trials.
Agreements and disagreements with other studies or reviews
To our knowledge, to date this is the only systematic review published on this topic.
AUTHORS’ CONCLUSIONS
Implications for practice
Currently the evidence supports delaying the timing of AAA repair until the aneurysm
reaches 5.5 cm in diameter. Findings from the four trials to date suggest no advantage to
early repair of small AAAs, irrespective of whether open or endovascular repair is used.
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Data regarding key factors for the management of small AAA (such as AAA size; patient
age, gender, and fitness) are much needed for the development of more definite and precise
guidelines. In particular, examining the survival effect of immediate surgery versus selective
surveillance for specific AAA size, AAA shape, and AAA location could reduce the
uncertainty regarding the management of small AAA. Future research regarding the
management of small AAAs should also focus on minorities and women as data regarding
these populations are lacking. In particular, future research should assess whether the AAA
management recommendations, which are based on studies in which women are under-
represented, are applicable to women given their smaller body frames and, therefore, smaller
abdominal aortas.
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CHARACTERISTICS OF STUDIES
Characteristics of included studies [ordered by study ID]
ADAM
Methods Study design: Intention to treat.
Method of randomisation: Equal probability of assignment to each of the two study groups using
automated telephone/computer.
Concealment of allocation: Unblinded.
Participants Country: United States.
Number: 1136.
Age: 50 - 79 years.
Sex: Men (n = 1126) and women (n = 10).
Inclusion criteria: Small (4.0 - 5.5 cm) non-tender asymptomatic AAAs considered fit for immediate
surgery. Patients who were considered unfit for immediate surgery, had symptoms associated the
aneurysm, were unable to attend the follow-up visit, or were unable to give informed consent were
excluded. Patients who received a revascularisation procedure within three months of enrolment,
who had a myocardial infarction within six months of enrolment, or who were expected to survive
less than five years because of invasive cancer or other life-threatening disease were also excluded
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Interventions Treatment: Surgery, n = 569 of whom 527 had immediate aneurysm repair: 42 had no elective
operation due to death, refusal, etc.
Surveillance, n = 567 of whom 349 had aneurysm repair when met the criteria listed below (in 9%,
the procedures were performed despite an AAA that did not meet the repair criteria listed below).
Patients assigned to the immediate surgery group received standard open repair within six weeks
after randomisation while patients assigned to selective surveillance were followed without repair at
similar regular intervals (at minimum once every six months) and surgery was performed within six
weeks if: a) the aneurysm reached 5.5 cm; or b) the aneurysm enlarged by a minimum of 0.7 cm in
six months or 1.0 cm in 1 year; or c) the aneurysm became symptomatic










Low risk Themethod of randomisation was of equal probability


















Low risk Unlikely given the study outcome (mortality) and low
lost of follow-up rate. Vital status was assessed using
the same methodology for both patients in the
immediate repair group and patients in the routine
ultrasound surveillance group -in case
misclassification occurred this would have been non-






Low risk Unlikely given the study outcome (mortality) and low




Low risk Authors published findings on all the study outcomes
including the study outcome of this review
Other bias Low risk We did not identify other possible risk of bias
CAESAR
Methods Study design: Intention to treat.
Method of randomisation: Randomisation was designed with equal probability (1:1 ratio) of
assignment to either early EVAR or surveillance by means of a computed generated random
number list, stratified by centre using a permuted block design and carried out online through the
internet.
Concealment of allocation: Unblinded.
Participants Country: Italy.
Number: 360.
Sex: Men (n = 345) and women (n = 15).
Age: 50 - 79 years.
Inclusion criteria: Patients with small (4.1 - 5.4 cm) asymptomatic AAAs, without high surgical
risk, and who would have benefited from early repair. Patients were excluded if they had severe
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co-morbidities or a suprarenal/thoracic aorta ≥ 4.0 cm, needed urgent repair, or were unable or
unwilling to give informed consent or follow the protocol
Interventions Treatment: Surgery, n = 182 of whom 175 had immediate EVAR surgery: 6 declined treatment
and 1 underwent open repair according to patient’s choice
Surveillance, n = 178 of whom 172 had aneurysm repair when met the criteria below (6 patients
had EVAR against protocol: 5 per patient choice and 1 with a surgeon not participating in the
study)
Patients assigned to early EVAR underwent aneurysm repair a median of 22 days after
randomisation while patients assigned to surveillance were seen every 6 months and repair
allowed if the aneurysm grew to 5.5 cm diameter in size, rapidly increased in diameter (> 1 cm/
year) or became symptomatic
Outcomes Primary: Mortality from any cause
Secondary: 1) aneurysm-related deaths (defined as and death caused directly or indirectly by
aneurysm rupture or aneurysm repair), 2) aneurysm rupture, 3) perioperative (30 days or inpatient)
or late adverse events (defined according to SVS/AAVS reporting standards) , 4) conversion to









Low risk Randomisation was designed with equal probability (1:1 ratio) of
assignment to either early EVAR or surveillance by means of a
computed-generated random number list, stratified by centre using a

















Low risk Unlikely given the study outcome (mortality) and low lost of follow-
up rate. Vital status was assessed using the same methodology for
both patients in the immediate repair group and patients in the routine
ultrasound surveillance group -in case misclassification occurred
thiswould have been non-differential and its impact on the study










Low risk Authors published findings on the main study outcome of this review
Other bias High risk Conflict of interests: Cook Medical, the sponsor of the study,
withdrew
PIVOTAL
Methods Study design: Intention to treat.
Method of randomisation: The randomisation procedure was created with equal probability of
assignment to each of the treatment groups by means of a computer-generated random-number code
Concealment of allocation: Unblinded.
Participants Country: United States.
Number: 728.
Sex: Men (n = 631) and women (n = 97).
Age: 40 - 90 years.
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Inclusion criteria: Patients with small (4.0-5.0 cm) AAAs. Patients were excluded from the study if
they had evidence of symptoms referable to the aneurysm, an abdominal or thoracic repair, an
aneurysm originating ≤ 1.0 cm from the most distal main renal artery, life expectancy of < 3 years,
inability to provide informed consent, predicted noncompliance with the protocol, Society of
Vascular Surgery (SVS) score > 2 with the exception of age and controlled hypertension, baseline
serum creatinine level > 2.5 mg/dL, or when the patient did not meet the indications for use of the
endograft device
Interventions Treatment: Surgery, n = 366 of whom 322 had immediate EVAR surgery: 4 underwent open
surgery, 6 underwent repair outside of the 30-day window of randomisation, 9 were withdrawn per
patient request, 10 were withdrawn per physician request for deteriorating health status between
randomisation and scheduled repair, 2 were treated with an endograft device that was not in the
protocol, and 13 received no repair for reasons not specified
Surveillance, n = 362 of whom 100 had aneurysm repair when met the criteria listed below
Patients assigned to early EVAR underwent aneurysm repair ≤ 30 days of randomisation while
patients assigned to surveillance were seen at 1 month, 6 months, and every 6 months thereafter for a
minimum of 36 months and a maximum of 60 months after operation. Patients were offered
aneurysm repair when symptoms thought referable to the aneurysm developed, when the diameter of
the aneurysm reached 5.5 cm, or when the aneurysm enlarged ≥0.5 cm between any two 6-month
assessments
Outcomes Primary: To determine whether early endovascular repair of aneurysms 4.0-5.0 cm in diameter is









Low risk The randomisation procedure was designed to provide
equal probability of assignment to each of the


















Low risk Unlikely given the study outcome (mortality) and low
lost of follow-up rate. Vital status was assessed using
the same methodology for both patients in the
immediate repair group and patients in the routine
ultrasound surveillance group - in case
misclassification occurred this would have been non-






Low risk Unlikely given the study outcome (mortality) and low




Low risk Authors published findings on the main study outcome
of this review
Other bias High risk Conflicts of interest: The study was funded by
Medtronic Vascular, which now holds the trial
database. The funding source was not specified in the
report of trial results, butwas specified in the 2009
paper describing the rationale and protocol for the
study (PIVOTAL). In addition, two members of the
research team were acknowledged as paid consultants
of Medtronic
UKSAT
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Methods Study design: Intention to treat.
Method of randomisation: Concealed randomisation using automated telephone/computer.
Concealment of allocation: Unblinded.
Participants Country: United Kingdom.
Number: 1090.
Sex: Men (n = 902) and women (n = 188).
Age: 60 - 76 years.
Inclusion criteria: Symptomless (non-tender) infrarenal aneurysm. Maximum A-P diameter 4.0 -
5.5 cm. Fit for elective surgery
Interventions Treatment: Surgery, n = 563 of whom 528 had immediate aneurysm repair; 35 had no elective
operation due to death, refusal, etc.
Control: Surveillance, n = 527 of whom 401 had aneurysm repair when met the criteria listed
below.
Patients assigned to the immediate surgery group received standard open repair within six weeks
after randomisation while patients assigned to selective surveillance were followed without repair
at similar regular intervals (at minimum once every six months) and surgery was performed within
six weeks if: a) the aneurysm reached 5.5 cm; or b) the aneurysm enlarged by a minimum 1.0 cm
in 1 year; or c) the aneurysm became tender or symptomatic




























Low risk Unlikely given the study outcome (mortality) and low
lost of follow-up rate. Vital status was assessed using
the same methodology for both patients in the
immediate repair group and patients in the routine
ultrasound surveillance group -in case
misclassification occurred this would have been non-






Low risk Unlikely given the study outcome (mortality) and low




Low risk Authors published findings on all the study outcomes
including the study outcome of this review
Other bias Low risk We did not identify other possible risk of bias
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Canadian Trial This trial was begun but stopped because of an inadequate rate of recruitment after n = 104 had been
enrolled (Cole CW, personal communication, 1998)
DATA AND ANALYSES
Comparison 1
Immediate repair (EVAR) versus ultrasound
surveillance at one year
Outcome or
subgroup title No. of studies No. of participants Statistical method Effect size
1 Mortality 2 831 Peto Odds Ratio (Peto, Fixed, 95%CI) 1.15 [0.59, 2.25]
Comparison 2
Immediate repair (open surgery) versus ultrasound
surveillance at one year
Outcome or
subgroup title No. of studies No. of participants Statistical method Effect size
1 Mortality 2 2226 Peto Odds Ratio (Peto, Fixed, 95%CI) 1.60 [1.10, 2.32]
Comparison 3
Immediate repair (either EVAR or OPEN) versus
ultrasound surveillance at one year
Outcome or
subgroup title No. of studies No. of participants Statistical method Effect size
1 Mortality 4 3057 Peto Odds Ratio (Peto, Fixed, 95%CI) 1.48 [1.07, 2.05]
Comparison 4
Immediate repair (open surgery) versus ultrasound
surveillance at six years
Outcome or
subgroup title No. of studies No. of participants Statistical method Effect size
1 Mortality 2 2226 Peto Odds Ratio (Peto, Fixed, 95%CI) 1.11 [0.91, 1.34]
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Costs of immediate repair versus ultrasound
surveillance
Outcome or subgroup
title No. of studies No. of participants Statistical method Effect size
1 Health service costs
(GBP) 1
Mean Difference (IV, Fixed,
95% CI) Totals not selected
WHAT’S NEW
Last assessed as up-to-date: 8 February 2012.
Date Event Description
17 October 2011 New search has been performed New author added
17 October 2011 New citation required but conclusions have not
changed
CAESAR and PIVOTAL results included in
the analysis
HISTORY
Protocol first published: Issue 3, 1999
Review first published: Issue 4, 1999
Date Event Description
20 May 2008 New search has been
performed
ADAM trial results incorporated in analysis. CAESAR and
PIVOTAL trials added to ongoing studies
8 April 2008 Amended Converted to new review format.
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Surgery for small abdominal aortic aneurysms that do not cause symptoms
An aneurysm is a ballooning of an artery (blood vessel), which can happen in the major
artery in the abdomen (aorta). The cause is unknown. Ruptured aneurysms cause death
unless surgical repair is rapid, which is difficult to achieve. Surgery for patients with
aneurysms more than 5.5 cm in diameter or who have associated pain is considered
necessary to relieve symptoms and to reduce the risk of rupture and death, although there
are risks associated with surgery. Surgical repair of the aneurysm consists of insertion of
a prosthetic inlay graft either by open surgery or endovascular repair.
Small asymptomatic abdominal aortic aneurysms are at low risk of rupture. They are
monitored through regular imaging so they can be surgically repaired if they
subsequently enlarge.
This review identified four well-conducted, controlled trials that randomised 3314
patients with small (diameter 4.0 to 5.5 cm) asymptomatic aneurysms in the abdominal
aorta to immediate repair or regular, routine ultrasounds to check for aneurysm growth
(‘surveillance’). Among the patients randomised to surveillance, the aneurysm was
repaired if it was enlarging, reached 5.5 cm in diameter, or became symptomatic The
trials did not show a meaningful difference in long-term survival between immediate
repair and selective surveillance over the 3 to 10 years of follow-up. The four trials
showed an early survival benefit in the surveillance group because of the number of
deaths within 30 days of surgery (operative mortality). Some 31% to 75% of the
participants randomised to surveillance eventually had the aneurysm repaired.
The results from the four trials conducted to date suggest no overall advantage to early
surgery for small abdominal aortic aneurysms (4.0 to 5.5 cm). The findings do not allow
additional guidance for ‘best-care’ management of subgroups of patients (based, for
example, on age, gender, or aneurysm diameter) since the trials did not provide data
allowing analysis of results in these subgroups. This is in relation to the intervention
versus control and the specified end-points. Furthermore, the more recent trials focused
on the efficacy of endovascular aneurysm repair and still failed to show a benefit. Thus,
both open and endovascular repair of small abdominal aortic aneurysms are not
supported by currently available evidence.
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Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented
as percentages across all included studies
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for
each included study
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Figure 3. Forest plot of comparison: Immediate repair (EVAR) versus ultrasound surveillance at
one year, outcome: 1.1 Mortality
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Figure 4. Forest plot of comparison: Immediate repair (open surgery) versus ultrasound
surveillance at one year, outcome: 2.1 Mortality
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Figure 5. Forest plot of comparison: Immediate repair (either EVAR or open surgery) versus
ultrasound surveillance at one year, outcome: 3.1 Mortality
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Figure 6. Forest plot of comparison: Immediate repair (open surgery) versus ultrasound
surveillance at six years, outcome: 4.1 Mortality
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